Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis
暂无分享,去创建一个
S. T. Olalla Saad | A. Jankowska | C. O'keefe | J. Maciejewski | A. Advani | M. Sekeres | M. Kalaycio | P. Elson | Yingchun Han | H. Makishima | F. Traina | V. Visconte | E. Copelan | R. Mali | R. Tiu | R. Kapur | A. Lichtin | H. Duong | F. Hsieh
[1] A. Jankowska,et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. , 2011, Blood.
[2] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[3] J. Licht,et al. DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.
[4] Li Ding,et al. Recurrent DNMT3A Mutations in Patients with Myelodysplastic Syndromes , 2011, Leukemia.
[5] J. Licht,et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.
[6] A. Jankowska,et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies , 2010, Leukemia.
[7] D. Birnbaum,et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia , 2010, British journal of haematology.
[8] O. Abdel-Wahab,et al. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration , 2010, Leukemia.
[9] A. Jankowska,et al. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations , 2010, British journal of haematology.
[10] A. Tefferi,et al. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 , 2010, Leukemia.
[11] A. Jankowska,et al. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome‐wide single nucleotide polymorphism array analysis , 2010, Genes, chromosomes & cancer.
[12] Tak W. Mak,et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations , 2010, The Journal of experimental medicine.
[13] A. Green,et al. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. , 2010, The New England journal of medicine.
[14] M. McDevitt,et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[16] S. Um,et al. ASXL1 Represses Retinoic Acid Receptor-mediated Transcription through Associating with HP1 and LSD1* , 2009, The Journal of Biological Chemistry.
[17] Jungwon Huh,et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. , 2009, Blood.
[18] E. Li,et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation , 2009, Nature Genetics.
[19] D. Gilliland,et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates , 2009, Leukemia.
[20] C. O'keefe,et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. , 2008, Blood.
[21] C. O'keefe,et al. Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes , 2007, Leukemia.
[22] M. Triggiani,et al. Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria , 2007, European journal of clinical investigation.
[23] A. Órfão,et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. , 2006, Blood.
[24] P. Valent,et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts , 2004, European journal of clinical investigation.
[25] A. Tefferi,et al. Clinical, genetic, and therapeutic insights into systemic mast cell disease , 2004, Current opinion in hematology.
[26] A. Tefferi,et al. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. , 2003, Leukemia research.
[27] Olivier Hermine,et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms , 2003, Oncogene.
[28] P. Lipsky,et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. , 2002, Blood.
[29] K. Lennert,et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.
[30] P. Valent,et al. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. , 2001, Leukemia research.
[31] L. Scott,et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. , 2000, Experimental hematology.
[32] B. Foster,et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). , 1999, Blood.
[33] J. Bernhard,et al. Mastocytosis , 1997, The Lancet.
[34] Y. Suzuki,et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.